Enhanced immune responses and protective immunity to Zika virus induced by a DNA vaccine encoding a chimeric NS1 fused with type 1 Herpes virus gD protein

dc.creatorPEREIRA, LENNON R.
dc.creatorALVES, RUBENS P. dos S.
dc.creatorSALES, NATIELY S.
dc.creatorANDREATA-SANTOS, ROBERT
dc.creatorVENCESLAU-CARVALHO, ALEXIA A.
dc.creatorPEREIRA, SAMUEL S.
dc.creatorCASTRO-AMARANTE, MARIA F.
dc.creatorRODRIGUES-JESUS, MONICA J.
dc.creatorFAVARO, MARIANNA T. de P.
dc.creatorCHURA-CHAMBI, ROSA M.
dc.creatorMORGANTI, LIGIA
dc.creatorFERREIRA, LUIS C. de S.
dc.date2020
dc.date2021-01-21T19:42:05Z
dc.date2021-01-21T19:42:05Z
dc.date.accessioned2023-09-28T14:17:41Z
dc.date.available2023-09-28T14:17:41Z
dc.identifier2673-3129
dc.identifierhttp://200.136.52.105/handle/123456789/31770
dc.identifier2
dc.identifier10.3389/fmedt.2020.604160
dc.identifierSem Percentil
dc.identifierSem Percentil CiteScore
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/9001993
dc.descriptionZika virus (ZIKV) is a globally-distributed flavivirus transmitted to humans by Aedes mosquitoes, usually causing mild symptoms that may evolve to severe conditions, including neurological alterations, such as neonatal microcephaly and Guillain-Barr?? syndrome. Due to the absence of specific and effective preventive methods, we designed a new subunit vaccine based on a DNA vector (pgDNS1-ZIKV) encoding the non-structural protein 1 (NS1) genetically fused to the Herpes Simplex Virus (HSV) glycoprotein D (gD) protein. Recombinant plasmids were replicated in Escherichia coli and the expression of the target protein was confirmed in transfected HEK293 cells. C57BL/6 and AB6 (IFNAR1???/???) mice were i.m. immunized by electroporation in order to evaluate pgDNS1-ZIKV immunogenicity. After two doses, high NS1-specific IgG antibody titers were measured in serum samples collected from pgDNS1-ZIKV-immunized mice. The NS1-specific antibodies were capable to bind the native protein expressed in infected mammalian cells. Immunization with pgDNS1-ZIKV increased both humoral and cellular immune responses regarding mice immunized with a ZIKV NS1 encoding vaccine. Immunization with pgDNS1-ZIKV reduced viremia and morbidity scores leading to enhanced survival of immunodeficient AB6 mice challenged with a lethal virus load. These results give support to the use of ZIKV NS1 as a target antigen and further demonstrate the relevant adjuvant effects of HSV-1 gD.
dc.descriptionFunda????o de Amparo ?? Pesquisa do Estado de S??o Paulo (FAPESP)
dc.descriptionCoordena????o de Aperfei??oamento de Pessoal de N??vel Superior (CAPES)
dc.descriptionFAPESP: 16/20045-7; 16/05570-8; 14/17595-0; 16/14344-1; 16/23560-0; 17/09661-0; 18/14459-9; 18/08199-4
dc.descriptionCAPES: 88887.473724/2020-00; 88887.185337/2018-00
dc.format1-14
dc.relationFrontiers in Medical Technology
dc.rightsopenAccess
dc.subjectviruses
dc.subjectzika virus
dc.subjectvaccines
dc.subjectimmunity
dc.subjectdna
dc.subjectproteins
dc.subjectinfluenza
dc.subjectinfluenza viruses
dc.subjectglycoproteins
dc.subjectherpes simplex
dc.subjectarthropods
dc.subjectenzyme immunoassay
dc.subjectmice
dc.titleEnhanced immune responses and protective immunity to Zika virus induced by a DNA vaccine encoding a chimeric NS1 fused with type 1 Herpes virus gD protein
dc.typeArtigo de peri??dico
dc.coverageI


Este ítem pertenece a la siguiente institución